Related Experiment Video
Updated: Jun 25, 2026
19:15
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
[Updating neonatal neurometabolic screening]
Israel Alfonso1, Gustavo Charria
1Departamento de Neurología, Miami Children's Hospital, Florida International University, Miami FL 33155, USA. ialfonso@pediatricneuro.com
Medicina
|February 26, 2009
Summary
Neurometabolic screening aims to detect treatable genetic disorders early. Methods like mass spectroscopy and genetic testing identify conditions such as phenylketonuria and cystic fibrosis in newborns.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Context:
- Newborn screening programs are crucial for public health.
- Early detection of metabolic disorders significantly improves patient outcomes.
- Current screening panels include a range of inherited conditions.
Purpose:
- To outline the objectives of neurometabolic screening.
- To detail the specific treatable disorders included in current screening protocols.
- To describe the analytical methodologies employed for diagnosis.
Summary:
- Neurometabolic screening focuses on the early identification of treatable inherited metabolic disorders.
- The current screening panel encompasses conditions like phenylketonuria, congenital hypothyroidism, galactosemia, and cystic fibrosis.
- Evaluations utilize advanced techniques including mass spectrometry and genetic testing.
Impact:
- Facilitates timely intervention, preventing severe health complications.
- Enhances the long-term prognosis and quality of life for affected individuals.
- Provides a foundation for expanding newborn screening capabilities.
